Insulinomimetic Effects of Tyrosine Kinase Inhibitors via PPAR-γ/Akt-Mediated β-Cell Preservation in Type 2 Diabetes Mellitus
This study demonstrates that certain tyrosine kinase inhibitors, particularly erlotinib, exhibit potent antidiabetic effects in type 2 diabetes by activating the PPAR-γ/Akt signaling pathway to improve glycemic control, reduce body weight, and preserve pancreatic β-cell function.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Type 2 diabetes is a condition where the body struggles to manage sugar levels, leading to high blood glucose that damages organs over time. This happens because the body becomes resistant to insulin, a hormone that acts like a key to unlock cells and let sugar in for energy, and because the pancreas slowly loses the ability to make enough of this hormone. For decades, doctors have treated this by trying to force the body to use insulin better or by replacing the missing hormone. However, the disease often keeps progressing, and finding new ways to protect the tiny cells in the pancreas that make insulin remains a major goal for researchers. Scientists have recently begun looking at a surprising group of drugs, originally designed to fight cancer, to see if they might help with diabetes. These drugs work by blocking specific enzymes called tyrosine kinases, which are involved in cell signaling. While these enzymes help cancer cells grow, blocking them might also calm down the inflammation and stress that damage insulin-producing cells in people with diabetes.
A team of researchers in India decided to test this idea by studying three of these cancer drugs: erlotinib, ruxolitinib, and upadacitinib. They wanted to see if these medicines could lower blood sugar and protect the pancreas in a way similar to a standard diabetes drug called pioglitazone. To do this, they first tested the drugs on fat cells grown in a lab dish to ensure they were safe and could help cells absorb sugar. They found that the drugs did not kill the cells and that erlotinib, in particular, helped the cells take in more sugar. Encouraged by this, the team moved to a living model of the disease: mice that are genetically prone to obesity and diabetes. These mice naturally develop high blood sugar and lose the ability to make insulin, much like humans with type 2 diabetes. The researchers divided the mice into groups, giving some the standard diabetes drug and others the three cancer drugs at a dose of 25 milligrams per kilogram of body weight, once a day for four weeks.
The results showed that the mice treated with the cancer drugs did not just survive; they showed signs of real metabolic improvement. The mice given erlotinib, ruxolitinib, and upadacitinib had lower blood sugar levels and better long-term sugar control compared to the sick mice that received no treatment. One of the most striking findings was how these drugs affected the animals' weight. While the standard diabetes drug caused the mice to gain weight, a common side effect of that medicine, the mice treated with the cancer drugs actually lost weight or gained less. They also ate less food. This suggests that these drugs might be fixing the underlying metabolic problems rather than just masking symptoms. The researchers also looked at the animals' blood and found that the treated mice had healthier levels of fats and cholesterol, and their liver enzymes, which indicate liver stress, returned to normal ranges.
Digging deeper into the biology, the team examined the tissues of the mice to see what was happening inside their bodies. They found that the mice treated with the drugs had higher levels of a protective protein called adiponectin and better markers for how the body burns energy. Most importantly, when they looked at the pancreas under a microscope, the mice treated with the drugs had much healthier insulin-producing cells. The sick mice had damaged, shrunken cells, but the treated mice had larger, more intact clusters of cells, indicating that the drugs helped preserve the pancreas. The researchers also found that the drugs increased the activity of a specific protein pathway in the liver that helps cells respond to insulin. This pathway acts as a signal chain that tells the body to take up sugar and stay healthy. The drug erlotinib was particularly effective at turning on this signal.
The study also looked at how the drugs affected the body's ability to handle stress and inflammation. In the sick mice, the body's natural defenses against oxidative stress were weak, but the treatment with the drugs boosted these defenses, making the liver and other tissues more resilient. The researchers concluded that these cancer drugs, particularly erlotinib, show strong potential as new treatments for type 2 diabetes because they lower blood sugar, protect the pancreas, and improve overall metabolic health without causing weight gain. While the study was conducted in mice and over a short period, the findings suggest that repurposing these existing medicines could offer a new strategy for managing diabetes. The researchers noted that more work is needed to confirm these results in humans and to understand the long-term safety, but the evidence from this study provides a compelling reason to explore these drugs further.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.